Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptomic analysis of decitabine induced HLAG+ regulatory T cells

ABSTRACT: Transcriptomic analysis of decitabine induced HLAG+ regulatory T cells

PROVIDER: PRJNA952653 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24084982.fastq.gz	Fastqsanger.gz
	SRR24084983.fastq.gz	Fastqsanger.gz
	SRR24084984.fastq.gz	Fastqsanger.gz
	SRR24084985.fastq.gz	Fastqsanger.gz
	SRR24084986.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 10

Similar Datasets

Transcriptomic analysis of decitabine induced HLAG+ regulatory T cells

Project description:To investigate the gene expression profile of decitabine induced HLAG+ regulatory T cells against their HLAG- counterparts

2023-04-07 | GSE229057 | GEO

Gene expression profile at single cell level of decitabine induced HLAG+ regulatory T cells

Project description:Decitabine induced HLAG+ regulatory T cells present a novel approach for adoptive cellular immunotherapy for immune mediated diseases. We used single cell RNA sequencing (scRNA-seq) to further dissect their molecular identity.

2023-04-07 | GSE229170 | GEO

Gene expression profile at single cell level of decitabine induced HLAG+ regulatory T cells

Project description:Gene expression profile at single cell level of decitabine induced HLAG+ regulatory T cells

| PRJNA953346 | ENA

Decitabine-induced DNA methylation-mediated transcriptomic reprogramming in human breast cancer cell lines

Project description:Decitabine-induced DNA methylation-mediated transcriptomic reprogramming in human breast cancer cell lines

| PRJEB56534 | ENA

HLA peptides (LC-MSMS) induced by Decitabine in Glioblastoma cell lines

Project description:Treatment of cancer cells with anti-cancer drugs often fails to achieve complete remission. Yet, such drug treatments may induce alteration in the tumor’s gene expression patterns, including those of Cancer/Testis Antigens (CTA). The degradation products of such antigens can be presented as HLA peptides on the surface of the tumor cells and be developed into anti-cancer immunotherapeutics. For example, the DNA methyl transferase inhibitor, 5-aza-2'-deoxycytidine (Decitabine) has limited anti-tumor efficacy, yet it induces the expression of many genes, including CTAs that are normally silenced in the healthy adult tissues. In this study, the presentation of many new HLA peptides derived from CTAs and induced by Decitabine was demonstrated in three human Glioblastoma cell lines. Such presentation of CTA-derived HLA peptides can be exploited for development of new treatment modalities, combining drug treatment with anti-CTA targeted immunotherapy. The Decitabine-induced HLA peptidomes include many CTAs that are not normally detected in healthy tissues or in cancer cells, unless treated with the drug. In addition, the study included large-scale analyses of the simultaneous effects of Decitabine on the transcriptomes, proteomes and HLA peptidomes of the human Glioblastoma cells. It demonstrates the poor correlations between these three levels of gene expression, both in their total levels and in their response to the drug.

2016-07-18 | PXD003790 | Pride

Decitabine-induced DNA methylation-mediated transcriptomic reprogramming in human breast cancer cell lines

Project description:Decitabine (DAC), a DNA methyltransferase (DNMT) inhibitor, is tested in combination with conventional anticancer drugs as a treatment option for various solid tumors.

2022-10-20 | E-MTAB-12225 | biostudies-arrayexpress

Transcriptomic profiling of KMT2A-rearranged infant acute lymphoblastic leukemia (ALL) cells after treatment witith azacitidine and decitabine.

Project description:Transcriptomic profiling was performed on six cell lines derived from infants with KMT2A-rearranged ALL following treatment with two hypomethylating drugs (azacitidine and decitabine) administered at low doses for 72 hours in vitro. We identified changes in gene expression following treatment with hypomethylating agents, with decitabine exerting a greater effect than azacitidine.

2022-12-31 | GSE212591 | GEO

Analysis of genome-wide methylation and gene expression induced by decitabine treatment in HL60 leukemia cell line

Project description:Epigenetic changes play a role in the pathogenesis of myeloid malignancies and hypomethylating agents have shown efficacy in these diseases. We studied the apoptotic effect, the genome-wide methylation and gene expression profiles in HL60 cells following decitabine treatment, using micro-array technologies. Decitabine treatment resulted in a decrease in global DNA methylation, corresponding to 4876 probeset IDs with significantly reduced methylation levels, while expression of 2583 IDs was induced. The integrated analysis identified 160 genes demethylated and upregulated by decitabine, mainly including development and differentiation pathways genes. Genes target of polycomb group protein regulation were overrepresented in this group. Apoptosis was induced by decitabine and apoptosis-specific PCR arrays more precisely indicated decitabine-induced upregulation of 13 apoptosis-related genes, in particular Dap-kinase 1 and Bcl2L10. Correspondingly, in primary patient samples, BCL2L10 was hypermethylated in 45% of AML, 43% of therapy-related myeloid neoplasms, 12% of MDS and in none of the controls.

2010-09-21 | GSE24224 | GEO

SUM159 BrCa Decitabine Gene Expression

Project description:Dysregulation of DNA methylation is an established feature of breast cancers. DNA demethylating therapies like decitabine are proposed for the treatment of triple-negative breast cancers (TNBCs) and indicators of response need to be identified. For this purpose, we characterized the effects of decitabine in a panel of 10 breast cancer cell lines and observed a range of sensitivity to decitabine that was not subtype-specific. Knockdown of potential key effectors demonstrated the requirement of deoxycytidine kinase (DCK) for decitabine response in breast cancer cells. In treatment-naive breast tumors, DCK was higher in TNBCs, and DCK levels were sustained or increased post chemotherapy treatment. This suggests that limited DCK levels will not be a barrier to response in TNBC patients treated with decitabine as a second line treatment or in a clinical trial. Methylome analysis revealed that genome-wide, region-specific, tumor suppressor gene-specific methylation, and decitabine-induced demethylation did not predict response to decitabine. Gene set enrichment analysis (GSEA) of transcriptome data demonstrated that decitabine induced genes within apoptosis, cell cycle, stress, and immune pathways in decitabine treated cells. Induced genes included those characterized by the viral mimicry response; however knockdown of key effectors of the pathway did not affect decitabine sensitivity suggesting that breast cancer growth suppression by decitabine is independent of viral mimicry. Finally, taxol-resistant breast cancer cells expressing high levels of multidrug resistance transporter ABCB1 remained sensitive to decitabine, suggesting that the drug could be used as second-line treatment for chemoresistant patients. We used microarrays to determine genome-wide expression changes induced by DNA de-methylating agent decitabine in breast cancer cell lines

2020-06-01 | GSE133987 | GEO

Decitabine-induced DNA methylation-mediated transcriptomic reprogramming in human breast cancer cell lines

Project description:JIMT-1 and T-47D cell lines, were transfected with a DCK expression vector and exposed to low-dose decitabine (DAC). DAC, a DNA methyltransferase (DNMT) inhibitor, is tested in combination with conventional anticancer drugs as a treatment option for various solid tumors.

2022-10-20 | E-MTAB-12224 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data